| Nov 18 |
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
|
| Nov 14 |
Galectin Therapeutics GAAP EPS of -$0.18
|
| Nov 14 |
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
|
| Oct 15 |
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
|
| Sep 30 |
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
|
| Sep 3 |
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 13 |
Galectin Therapeutics GAAP EPS of -$0.20
|
| Aug 13 |
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
|
| Aug 1 |
Galectin Therapeutics appoints Khurram Jamil as chief medical officer
|
| Aug 1 |
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
|
